<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="102979"><DrugName>quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</DrugName><DrugNamesKey><Name id="43152423">MenQuadfi</Name></DrugNamesKey><DrugSynonyms><Name><Value>quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Value></Name><Name><Value>MenACYW conjugate vaccine, Sanofi Pasteur</Value></Name><Name><Value>Meningococcal polysaccharide (Serogroups A, C, Y, and W) Tetanus toxoid conjugate vaccine, Sanofi Pasteur</Value></Name><Name><Value>MenACYW-TT</Value></Name><Name><Value>MenQuadfi</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="30640">Sanofi Pasteur Inc</CompanyOriginator><CompaniesPrimary><Company id="30640">Sanofi Pasteur Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="30640" type="Company"><TargetEntity id="4298219387" type="organizationId">Sanofi Pasteur Inc</TargetEntity></SourceEntity><SourceEntity id="206" type="ciIndication"><TargetEntity id="10027199" type="MEDDRA"/><TargetEntity id="D008581" type="MeSH"/><TargetEntity id="-1765797396" type="omicsDisease"/><TargetEntity id="892" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="PR">Pre-registration</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="206">Meningitis</Indication></IndicationsPrimary><ActionsSecondary><Action id="12378">Prophylactic vaccine</Action><Action id="12372">Protein subunit vaccine</Action><Action id="12373">Polysaccharide subunit vaccine</Action></ActionsSecondary><Technologies><Technology id="159">Oligosaccharide</Technology><Technology id="207">Protein conjugated</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2019-07-01T12:19:42.000Z</LastModificationDate><ChangeDateLast>2019-07-03T00:00:00.000Z</ChangeDateLast><AddedDate>2016-07-29T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="30640" linkType="Company"&gt;Sanofi Pasteur&lt;/ulink&gt; is  developing MenQuadfi, a polysaccharide quadrivalent meningococcal  vaccine, solution for injection intramuscular, comprised of serogroups A, C, Y and W conjugated to tetanus toxoid, for the potential im prevention of  meningitis [&lt;ulink linkID="1783587" linkType="Reference"&gt;1783587&lt;/ulink&gt;], [&lt;ulink linkID="2168442" linkType="Reference"&gt;2168442&lt;/ulink&gt;]. In June 2019, the FDA had accepted a BLA filing for review [&lt;ulink linkID="2168442" linkType="Reference"&gt;2168442&lt;/ulink&gt;]. In October 2017, an additional phase III trial was completed [&lt;ulink linkID="1873529" linkType="Reference"&gt;1873529&lt;/ulink&gt;]. In October 2018, another phase III trial was initiated in infants and toddlers [&lt;ulink linkID="2064537" linkType="Reference"&gt;2064537&lt;/ulink&gt;]. In February 2019, another phase III trial was initiated in potential pilgrims aged 56 years and older [&lt;ulink linkID="2128877" linkType="Reference"&gt;2128877&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;REGULATORY INFORMATI	ON&lt;/subtitle&gt;In June 2019, the FDA had accepted a BLA filing for the prevention of meningococcal meningitis for review. At that time, the target PDUFA date was April 25, 2020 [&lt;ulink linkID="2168442" linkType="Reference"&gt;2168442&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In February 2019, an open-label, single group assignment, interventional, phase III trial (&lt;ulink linkID="372994" linkType="Protocol"&gt;NCT03869866&lt;/ulink&gt;; MEQ00063; U1111-1183-6163) was initiated in Turkey to assess the immunogenecity and safety of the vaccine in potential pilgrims              (expected n = 330) aged 56 years and older. The primary end point was to measure antibody titers &amp;gt;/= 1:8 against meningococcal serogroups A, C, Y and W by serum bactericidal assay using human complement. At that time, the trial was expected to complete in October 2019 [&lt;ulink linkID="2128877" linkType="Reference"&gt;2128877&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2018,a randomized, interventional, parallel assignment, prevention phase III trial (&lt;ulink linkID="350238" linkType="Protocol"&gt;NCT03632720&lt;/ulink&gt;; MET52; 2017-004520-30; U1111-1183-6530)   was to begin in the UK to assess the immunogenicity and safety of the vaccine  in infants and toddlers (expected n = 700) when administered using a 1+1 schedule in a National Immunization Schedule having a meningococcal group B vaccine (Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine, Human rotavirus &lt;ulink linkID="12813" linkType="Drug"&gt;RIX-4414&lt;/ulink&gt; strain vaccine and Pneumococcal 13-valent polysaccharide conjugate vaccine) as standard of care. The primary endpoint was to  demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, W, and Y when MenACYW conjugate vaccine was administered concomitantly with a licensed meningococcal group B vaccine  in the second year of life compared to when MenACYW conjugate vaccine was given alone. At that time, the  trial was expected to complete in December 2020. In October 2018, the trial was initiated [&lt;ulink linkID="2064537" linkType="Reference"&gt;2064537&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, an interventional, randomized, phase III study (&lt;ulink linkID="278270" linkType="Protocol"&gt;NCT02955797&lt;/ulink&gt;; MET51 U1111-1161-2935 2016-000749-30) was planned in February 2016 in Finland, Hungary and Spain to asses the safety and efficacy of the vaccine when used as a single-dose toddler vaccine in individuals (expected n = 918) who were either meningococcal vaccine naive or had received one or more doses of monovalent meningococcal C vaccines during infancy. At that time, the study was expected to complete in April 2018 [&lt;ulink linkID="1873529" linkType="Reference"&gt;1873529&lt;/ulink&gt;]. In April 2017, the trial was initiated in Finland, Germany, Hungary, and Spain [&lt;ulink linkID="1873529" linkType="Reference"&gt;1873529&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2016, a phase III trial (163300410A0093; MET57) was planned to be initiated in Republic of Korea, Russia and Mexico in subjects (expected n = 1200) with meningitis to assess the immunogenicity of the conjugate vaccine administered alone or MenACYW concomitantly with licensed pediatric vaccines [&lt;ulink linkID="1876721" linkType="Reference"&gt;1876721&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2016, a randomized, double-blind, phase III study (&lt;ulink linkID="266423" linkType="Protocol"&gt;NCT02842866&lt;/ulink&gt;;  MET49) to assess the safety,  efficacy and immunogenicity of the vaccine compared to &lt;ulink linkID="51015" linkType="Drug"&gt;Menomune&lt;/ulink&gt;, was initiated in the US and Puerto Rico, in patients (expected n = 900) with meningitis. The study was completed in February 2017  [&lt;ulink linkID="1783587" linkType="Reference"&gt;1783587&lt;/ulink&gt;]. In October 2018, clinical data were presented at the 2018 IDWeek in San Francisco, CA. Between MenACYW-TT conjugate vaccine and Menomune, non-inferiority of immune responses was observed based on percentage of subjects who achieved vaccine sero-response for serogroups A, C, W and Y at day 30 compared to baseline. Safety concerns were not identified during the study. Immediate hypersensitivity reactions and vaccine-related serious adverse events were not reported [&lt;ulink linkID="2078254" linkType="Reference"&gt;2078254&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2018, results from a phase II, randomized, open label, parallel-group, multicenter study evaluating the immunogenicity and safety of MenACYW-TT were presented  at the 2018 IDWeek in San Francisco, CA. Subjects (n = 1715) in groups 1, 2, 3 and 4 were randomized to receive one dose of MenACYW-TT conjugate vaccine, one dose of control MCV4 vaccine, one dose of MenACYW-TT conjugate vaccine co administered with Tdap and HPV4 and Tdap and HPV4 vaccines, respectively. In all four serogroups (A, C, W and Y), the proportions of individuals with hSBA &amp;gt;/= 1:8 after MenACYW-TT conjugate vaccine administration were higher than MCV4-CRM administration (A: 93.5 versus 82.8%; C: 98.5 versus 76.0%; W: 99.1 versus 90.7%; Y: 97.2% versus 83.2%, respectively). Most unsolicited adverse events reported were grade 1 or 2 in intensity [&lt;ulink linkID="2078163" linkType="Reference"&gt;2078163&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In March 2019, the EMA's Pediatric Committee adopted a positive opinion on modifications to a PIP for the prevention of meningococcal disease [&lt;ulink linkID="2138426" linkType="Reference"&gt;2138426&lt;/ulink&gt;]. In April 2019, the EMA's Pediatric Committee adopted  a revised  positive opinion  following the re-examination, and agreed to the changes regarding the measures of the paediatric investigation plan,  for MenACYW, for the prevention of invasive meningococcal disease [&lt;ulink linkID="2157800" linkType="Reference"&gt;2157800&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="30640">Sanofi Pasteur Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2019-06-27T00:00:00.000Z</StatusDate><Source id="2168442" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30640">Sanofi Pasteur Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2019-02-20T00:00:00.000Z</StatusDate><Source id="2128877" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30640">Sanofi Pasteur Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2017-04-24T00:00:00.000Z</StatusDate><Source id="1873529" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30640">Sanofi Pasteur Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2018-07-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30640">Sanofi Pasteur Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2018-07-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30640">Sanofi Pasteur Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2018-07-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30640">Sanofi Pasteur Inc</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2018-07-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="30640">Sanofi Pasteur Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2016-11-03T00:00:00.000Z</StatusDate><Source id="1873529" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30640">Sanofi Pasteur Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2016-07-20T00:00:00.000Z</StatusDate><Source id="1783587" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30640">Sanofi Pasteur Inc</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2016-07-20T00:00:00.000Z</StatusDate><Source id="1783587" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30640">Sanofi Pasteur Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2016-08-05T00:00:00.000Z</StatusDate><Source id="1876721" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30640">Sanofi Pasteur Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2016-08-05T00:00:00.000Z</StatusDate><Source id="1876721" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30640">Sanofi Pasteur Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2016-08-05T00:00:00.000Z</StatusDate><Source id="1876721" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="30640">Sanofi Pasteur Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="206">Meningitis</Indication><StatusDate>2018-07-18T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><OwnerCompany id="1009547">Sanofi SA</OwnerCompany><Country id="EU">EU</Country><Indication id="206">Meningitis</Indication><AwardedIndication>Prevention of invasive meningococcal disease </AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2019-04-26T00:00:00.000Z</MileStoneDate><Source id="2157800" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="3944287" number="WO-2018027123" title="Multivalent pneumococcal polysaccharide-protein conjugate composition"/><PatentFamily id="3944289" number="WO-2018027126" title="Multivalent pneumococcal polysaccharide-protein conjugate composition"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SK Group" id="26891"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>